NPS Preos Fracture Reduction, Bone Mineral Density Phase III Data To Top Off Late-2004 NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is still seeking a co-promotion partner for the osteoporosis agent. The pivotal study shows significant relative reduction in vertebral fracture risk and change in bone mineral density.
You may also be interested in...
Preos “Approvable” Pending Additional Clinical Data, NPS Says
FDA concerns regarding hypercalcemia and Preos’ injection device call for additional safety information for the osteoporosis therapy.
Preos “Approvable” Pending Additional Clinical Data, NPS Says
FDA concerns regarding hypercalcemia and Preos’ injection device call for additional safety information for the osteoporosis therapy.
NPS Postpones Preos Filing To Add Two-Year Data From PaTH Study
NDA submission for the osteoporosis agent was originally slated for year-end 2004. Firm says two-year results have implications for use of Preos (recombinant parathyroid hormone) with Fosamax (alendronate).